Scinopharm Taiwan (TPE:1789) Construction In Progress: NT$145 Mil (As of Dec. 2025)


TPE:1789 Scinopharm Taiwan Ltd TPE:1789
76 GF Score
Price NT$20.50
GF Value NT$27.02
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Scinopharm Taiwan Construction In Progress?

Scinopharm Taiwan TPE:1789 +2.50% 76 Construction In Progress is NT$145 Mil as of Dec. 2025. GuruFocus rates TPE:1789 with a GF Score™ of 76/100 and a GF Value™ of NT$27.02 (Modestly Undervalued). The stock has 7 warning signs investors should review.

Scinopharm Taiwan's quarterly construction in progress increased from Jun. 2025 (NT$79 Mil) to Sep. 2025 (NT$88 Mil) and increased from Sep. 2025 (NT$88 Mil) to Dec. 2025 (NT$145 Mil).

Scinopharm Taiwan's annual construction in progress declined from Dec. 2023 (NT$178 Mil) to Dec. 2024 (NT$151 Mil) and declined from Dec. 2024 (NT$151 Mil) to Dec. 2025 (NT$145 Mil).

Scinopharm Taiwan Construction In Progress Historical Data

* Premium members only.

The historical data trend for Scinopharm Taiwan's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scinopharm Taiwan Construction In Progress Chart

Scinopharm Taiwan Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 235.28 299.47 178.15 150.89 144.63

Scinopharm Taiwan Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 150.89 104.55 79.11 87.83 144.63
TPE:1789
76GF Score
Scinopharm Taiwan Ltd TPE:1789
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scinopharm Taiwan Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of NT$145 Mil mean?
Scinopharm Taiwan (TPE:1789) has a Construction In Progress of NT$145 Mil as of Dec. 2025. Construction in Progress records the amount of construction work that is not complete. View historical data on Scinopharm Taiwan and its competitors.
Is Scinopharm Taiwan's Construction In Progress too high?
Scinopharm Taiwan's current Construction In Progress is NT$145 Mil. Overall, Scinopharm Taiwan has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Scinopharm Taiwan's Construction In Progress compare to ZTS and UTHR?
Scinopharm Taiwan's Construction In Progress of NT$145 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Drug Manufacturers company?
A good Construction In Progress depends on the Drug Manufacturers industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Scinopharm Taiwan and its competitors. Scinopharm Taiwan's current Construction In Progress is NT$145 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scinopharm Taiwan stock overvalued right now?
Based on GuruFocus' analysis, Scinopharm Taiwan (TPE:1789) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$27.02, compared to a current price of NT$20.50 — trading 24.1% below its estimated fair value. The current Construction In Progress is NT$145 Mil. Scinopharm Taiwan's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Scinopharm Taiwan (TPE:1789), the current Construction In Progress is NT$145 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Scinopharm Taiwan (TPE:1789) Overvalued in 2026?

Based on GuruFocus' analysis, Scinopharm Taiwan stock appears to be undervalued. The current stock price of NT$20.50 is trading 24.1% below its estimated GF Value™ of NT$27.02. GuruFocus considers Scinopharm Taiwan to be Modestly Undervalued.

Key valuation signals for TPE:1789:

  • Construction In Progress: NT$145 Mil
  • GF Value™: NT$27.02 vs. price of NT$20.50 (24.1% below fair value)
  • GF Score™: 76/100 with 7 warning signs

No single metric tells the full story. See the TPE:1789 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Scinopharm Taiwan Business Description

Address Nan-Ke 8th Road, No. 1, Southern Taiwan Science Park, Shan-Hua, Tainan, TWN, 74144
Scinopharm Taiwan Ltd is mainly engaged in the manufacture of western medicines and other chemical materials, biological technology services, intellectual property rights, international trade, and the research, development, production, manufacture, and sales of Active Pharmaceutical Ingredients (API), albumin medicines, oligonucleotide medicines, peptide medicines, injections, and new small molecule drugs. The Company also provides related consulting and technical services and international trade for the above products. In addition, the Company sells chemical material reprocessed from material recycled from the Company's manufacturing process.
76GF Score

Get the complete analysis for TPE:1789

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$20.50
Price
NT$27.02
GF Value